APA (7th ed.) Citation

Schiopu, E., Chatterjee, S., Hsu, V., Flor, A., Cimbora, D., Patra, K., . . . Herbst, R. (2016). Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: A phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis research & therapy, 18(1), 131. https://doi.org/10.1186/s13075-016-1021-2

Chicago Style (17th ed.) Citation

Schiopu, Elena, et al. "Safety and Tolerability of an Anti-CD19 Monoclonal Antibody, MEDI-551, in Subjects with Systemic Sclerosis: A Phase I, Randomized, Placebo-controlled, Escalating Single-dose Study." Arthritis Research & Therapy 18, no. 1 (2016): 131. https://doi.org/10.1186/s13075-016-1021-2.

MLA (9th ed.) Citation

Schiopu, Elena, et al. "Safety and Tolerability of an Anti-CD19 Monoclonal Antibody, MEDI-551, in Subjects with Systemic Sclerosis: A Phase I, Randomized, Placebo-controlled, Escalating Single-dose Study." Arthritis Research & Therapy, vol. 18, no. 1, 2016, p. 131, https://doi.org/10.1186/s13075-016-1021-2.